External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>Biopharma company LABP targeted for takeover by AbbVie with offer of $20.42 cash per share and CVR potentially worth over $11</li><li>Deal valued at $137.5 million in cash and $75 million in contingent value rights, expected to close in Q2 2024</li><li>CVR presents opportunity for potentially lucrative payout but comes with risks associated with illiquid securities</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Biopharma company LABP targeted for takeover by AbbVie with offer of $20.42 cash per share and CVR potentially worth over $11Deal valued at $137.5 million in cash and $75 million in contingent value rights, expected to close in Q2 2024CVR presents opportunity for potentially lucrative payout but comes with risks associated with illiquid securitiesThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Landos Biopharma Inc (LABP) - Tuesday, Apr 16, 2024

United States

Landos Biopharma, Inc. operates as a pharmaceutical company. The Company discovers and develops oral therapeutics for patients with autoimmune diseases. Landos Biopharma serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00